Table 5. Correlations between expression of enzymes associated with glycine metabolism and clinicopathological characteristics.
| Parameters | SHMT1 in tumor | SHMT1 in stroma | GLDC in tumor | GLDC in stroma | ||||||||
| Negative n = 598 (%) | Positive n = 111 (%) | P-value* | Negative n = 310 (%) | Positive n = 399 (%) | P-value* | Negative n = 370 (%) | Positive n = 339 (%) | P-value* | Negative n = 621 (%) | Positive n = 88 (%) | P-value* | |
| Age (yr, mean ±SD) | 50.2±10.9 | 46.9±10.7 | 0.032 | 49.8±11.7 | 49.6±10.3 | 6.448 | 48.5±11.0 | 50.9±10.7 | 0.024 | 49.6±10.9 | 50.0±10.8 | 6.072 |
| Histologic grade | <0.001 | 1.168 | 4.600 | 0.416 | ||||||||
| I/II | 431 (72.1) | 46 (41.4) | 218 (70.3) | 259 (64.9) | 245 (66.2) | 232 (68.4) | 426 (68.6) | 51 (58.0) | ||||
| III | 167 (27.9) | 65 (58.6) | 92 (29.7) | 140 (35.1) | 125 (33.8) | 107 (31.6) | 195 (31.4) | 37 (42.0) | ||||
| ER | <0.001 | 6.024 | 2.176 | 6.496 | ||||||||
| Negative | 164 (27.4) | 90 (81.1) | 109 (35.2) | 145 (36.3) | 140 (37.8) | 114 (33.6) | 224 (36.1) | 30 (34.1) | ||||
| Positive | 434 (72.6) | 21 (18.9) | 201 (64.8) | 254 (63.7) | 230 (62.2) | 225 (66.4) | 397 (63.6) | 58 (65.9) | ||||
| PR | <0.001 | 5.200 | 0.024 | 6.568 | ||||||||
| Negative | 253 (42.3) | 68 (77.5) | 145 (46.8) | 194 (48.6) | 197 (53.2) | 142 (41.9) | 298 (48.0) | 41 (46.6) | ||||
| Positive | 345 (57.7) | 25 (22.5) | 165 (53.2) | 205 (51.4) | 173 (46.8) | 197 (58.1) | 323 (52.0) | 47 (53.4) | ||||
| HER-2 | 1.024 | <0.001 | 0.128 | <0.001 | ||||||||
| Negative | 467 (78.1) | 94 (84.7) | 269 (86.8) | 292 (73.2) | 306 (82.7) | 255 (75.2) | 506 (81.5) | 55 (62.5) | ||||
| Positive | 131 (21.9) | 17 (15.3) | 41 (13.2) | 107 (26.8) | 64 (17.3) | 84 (24.8) | 115 (18.5) | 33 (37.5) | ||||
| Tumor stage | 0.392 | 2.312 | 0.008 | 4.560 | ||||||||
| T1 | 300 (50.2) | 44 (39.6) | 143 (46.1) | 201 (50.4) | 158 (42.7) | 186 (54.9) | 304 (49.0) | 40 (45.5) | ||||
| T2/T3 | 298 (49.8) | 67 (60.4) | 167 (53.9) | 198 (49.6) | 212 (57.3) | 153 (45.1) | 317 (51.0) | 48 (54.5) | ||||
| Nodal stage | 0.736 | 6.064 | 5.176 | 0.216 | ||||||||
| N0 | 345 (57.7) | 74 (66.7) | 181 (58.4) | 238 (59.6) | 222 (60.0) | 197 (58.1) | 377 (60.7) | 42 (47.7) | ||||
| N1/N2/N3 | 253 (42.3) | 37 (33.3) | 129 (41.6) | 161 (40.4) | 148 (40.0) | 142 (41.9) | 244 (39.3) | 46 (52.3) | ||||
| Ki-67 LI (%, mean ± SD) | 14.5±16.0 | 32.9±22.6 | <0.001 | 16.4±19.5 | 18.1±17.6 | 1.800 | 19.6±19.7 | 14.9±16.7 | 0.008 | 17.3±18.8 | 18.0±15.8 | 5.808 |
| Tumor recurrence | 2.200 | 0.880 | 0.136 | 5.504 | ||||||||
| Absent | 548 (91.6) | 98 (88.3) | 276 (89.0) | 370 (92.7) | 328 (88.6) | 318 (93.8) | 567 (91.3) | 79 (89.8) | ||||
| Present | 50 (8.4) | 13 (11.7) | 34 (11.0) | 29 (7.3) | 42 (11.4) | 21 (6.2) | 54 (8.7) | 9 (10.2) | ||||
| Death | 1.504 | 0.104 | 1.392 | 8.000 | ||||||||
| Survival | 552 (92.3) | 98 (88.3) | 275 (88.7) | 375 (94.0) | 334 (90.3) | 316 (93.2) | 569 (91.6) | 81 (92.0) | ||||
| Death | 46 (7.7) | 13 (11.7) | 35 (11.3) | 24 (6.0) | 36 (9.7) | 23 (6.8) | 52 (8.4) | 7 (8.0) | ||||
*p-value was corrected by the Bonferroni method.